Johnson & Johnson Deferred Compensation Liability, Current and Noncurrent
Johnson & Johnson (JNJ) had Deferred Compensation Liability, Current and Noncurrent of $44.00 million as of 2025-12-28, per its 10-K filed 2026-02-11.
Financial Statements › Balance Sheet › Liabilities
us-gaap:DeferredCompensationLiabilityCurrentAndNoncurrent · last filed 2026-02-11
- 2025-12-28: Deferred Compensation Liability, Current and Noncurrent $44.00M.
- 2024-12-29: Deferred Compensation Liability, Current and Noncurrent $49.00M.
- 2023-12-31: Deferred Compensation Liability, Current and Noncurrent $68.00M.
- 2023-01-01: Deferred Compensation Liability, Current and Noncurrent $100.00M.
| Period end | Deferred Compensation Liability, Current and Noncurrent |
|---|---|
| 2025-12-28 | $44.00M 10-K · filed 2026-02-11 |
| 2024-12-29 | $49.00M 10-K · filed 2026-02-11 |
| 2023-12-31 | $68.00M 10-K · filed 2025-02-13 |
| 2023-01-01 | $100.00M 10-K · filed 2024-02-16 |
| 2022-01-02 | $181.00M 10-K · filed 2023-02-16 |
| 2021-01-03 | $250.00M 10-K · filed 2022-02-17 |
| 2019-12-29 | $338.00M 10-K · filed 2021-02-22 |
| 2018-12-30 | $410.00M 10-K · filed 2020-02-18 |
| 2017-12-31 | $475.00M 10-K · filed 2019-02-20 |
| 2017-01-01 | $534.00M 10-K · filed 2018-02-21 |
| 2016-01-03 | $584.00M 10-K · filed 2017-02-27 |
| 2014-12-28 | $599.00M 10-K · filed 2016-02-24 |
| 2013-12-29 | $693.00M 10-K · filed 2015-02-24 |
| 2012-12-30 | $747.00M 10-K · filed 2014-02-21 |
| 2012-01-01 | $863.00M 10-K · filed 2013-02-22 |
| 2011-01-02 | $820.00M 10-K · filed 2012-02-23 |
| 2010-01-03 | $790.00M 10-K · filed 2011-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ELI LILLY & Co (LLY) | United States | $1,113.804B | 42.28 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |